CPC A61K 31/702 (2013.01) [A61P 21/06 (2018.01)] | 10 Claims |
1. A method for treating muscular atrophy, the method comprising administering a composition comprising 2′-fucosyllactose (2′-FL) as an active ingredient to a subject in need thereof,
wherein the subject suffers from:
(i) primary muscular atrophy which is induced by a lack of mechanical stimulation, decreased activity of neuromuscular junctions, decreased mitochondrial function, or nutritional deficiency, or
(ii) secondary muscular atrophy which is induced by denervation due to stroke, excessive drug use, or changes in endocrine system hormones and sex hormones,
wherein the subject requires increasing muscle differentiation or increasing a weight of muscle tissue, and
wherein the 2′-fucosyllactose is administered at a dosage of 400 mg/kg/day based on a body weight of the subject.
|